Posted by Michael Wonder on 05 Dec 2017
Novartis and Roche get NICE rejections
5 December 2017 - There was disappointing news today for Swiss pharma giants Novartis and Roche when the UK’s NICE published draft guidance on technology appraisals turning down drugs from the companies for regular use on the National Health Service.
The medicines cost-effectiveness watchdog announced that tocilizumab, marketed by Roche under the brand name RoActemra in Europe, is not recommended to treat giant cell arteritis.
NICE also announced that Novartis’ Rydapt (midostaurin) is not recommended to treat a specific type of acute myeloid leukaemia.
